Pharmacogenomic Effect/ADR for Citalopram (DBSNPE004979)

Identifier
DBSNPE004979
Drug
Citalopram (DB00215)
Interacting Gene/Enzyme
Cytochrome P450 2C19
Gene Name
CYP2C19
UniProt ID
P33261
Defining Change(s)
1297C>Trs56337013
Allele Name
CYP2C19*5
Genotype(s)
Not Available
Type(s)
ADR Inferred
Groups
Non-functional CYP2C19
Description
Poor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.
References
  1. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. [Article]
  2. Celexa® (citalopram hydrobromide)[package insert]. Irvine, California: Allergan USA, Inc.; 2017. [Link]